<DOC>
	<DOCNO>NCT00058201</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know chemotherapy regimen effective , whether chemotherapy effective observation , treat pancreatic cancer surgery . PURPOSE : Phase III trial compare effectiveness two chemotherapy regimen therapy treat patient completely resect pancreatic cancer .</brief_summary>
	<brief_title>Two Chemotherapy Regimens Compared With Observation Treating Patients With Completely Resected Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy adjuvant gemcitabine v fluorouracil leucovorin calcium ( vs observation patient ampullary pancreatic malignancy ) , term overall survival , patient completely resect pancreatic cancer . Secondary - Compare toxicity regimens patient . - Compare quality life 5-year survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord histology ( ductal adenocarcinoma v ampullary pancreatic malignancy ) , resection margin status , participate country . Patients randomize 1 2 treatment arm . Randomization patient ampullary pancreatic malignancy include observation arm . - Arm I : Patients receive leucovorin calcium IV fluorouracil IV day 1-5 . - Arm II : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 . - Arm III ( patient ampullary pancreatic malignancy ) : Patients undergo observation . Treatment arm I II repeat every 28 day 6 course absence disease progression unacceptable toxicity . Quality life assess baseline , 3 , 6 , 12 month , annually 5 year . Patients follow every 3 month . PROJECTED ACCRUAL : A total 1,030 patient pancreatic adenocarcinoma ( 515 per arm I II ) accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ductal adenocarcinoma pancreas OR Histologically confirm diagnosis 1 follow type cancer : Acinar cell carcinoma cystadenocarcinoma pancreas Cancers periampullary region Cancers intrapancreatic part bile duct Periampullary cancer uncertain origin Complete macroscopic resection ( R0 R1 resection ) Histological examination resection margin require No stage IVB disease No evidence malignant ascites No liver peritoneal metastases No evidence spread distant abdominal extraabdominal organ No pancreatic lymphoma PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy More 3 month Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant Able participate longterm followup No prior concurrent malignancy except curatively treat basal cell skin cancer carcinoma situ cervix No serious medical psychological condition would preclude study treatment PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No neoadjuvant chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery See Disease Characteristics Recovered prior resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>acinar cell adenocarcinoma pancreas</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>